WO2005095403B1 - Macrocyclic compounds as inhibitors of viral replication - Google Patents
Macrocyclic compounds as inhibitors of viral replicationInfo
- Publication number
- WO2005095403B1 WO2005095403B1 PCT/US2005/010494 US2005010494W WO2005095403B1 WO 2005095403 B1 WO2005095403 B1 WO 2005095403B1 US 2005010494 W US2005010494 W US 2005010494W WO 2005095403 B1 WO2005095403 B1 WO 2005095403B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- group
- methods
- inhibitors
- viral replication
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000002678 macrocyclic compounds Chemical class 0.000 title 1
- 230000029812 viral genome replication Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 15
- 239000000203 mixture Substances 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010057199 Flaviviral infection Diseases 0.000 abstract 1
- 241000711549 Hepacivirus C Species 0.000 abstract 1
- 210000004185 Liver Anatomy 0.000 abstract 1
- 208000001756 Virus Disease Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Abstract
The embodiments provide macrocylic compounds, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
Claims
AMENDED CLAIMS
[received by the International Bureau on 09 December 2005 (09.12.05); new claims 201 to 212 added, remaining claims unchanged, (1 page)]
201. The compound of claim 174 in which L is selected from the group consisting Of -OCH2- and -NHCH2-.
202. The compound of claim 174 in which L is selected from the group consisting of -CH=CH- and -C≡C-.
203. The compound of claim 174 in which L is selected from the group consisting Of -SCH2-, -SO2-, and -CH2SO-.
204. The compound of claim 174 in which L is selected from the group consisting of -WC(=V)-NH- and -WC(=V)-O-, where V and W are each individually selected from O, S or NH.
205. The compound of claim 182 in which L is selected from the group consisting
206. The compound of claim 182 in which L is selected from the group consisting Of -CH=CH- and -C≡C-.
207. The compound of claim 182 in which L is selected from the group consisting Of -SCH2-, -SO2-, and -CH2SO-.
208. The compound of claim 182 in which L is selected from the group consisting of -WC(=V)-NH- and -WC(=V)-O-, where V and W are each individually selected from O, S orNH.
209. The compound of claim 189 in which L is selected from the group consisting of -OCH2- and -NHCH2-.
210. The compound of claim 189 in which L is selected from the group consisting Of -CH=CH- and -C≡C-.
211. The compound of claim 189 in which L is selected from the group consisting Of -SCH2-, -SO2-, and -CH2SO-.
212. The compound of claim 189 in which L is selected from the group consisting of -WC(=V)-NH- and -WC(=V)-O-, where V and W are each individually selected from O, S or NH.
444
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0509467-4A BRPI0509467A (en) | 2004-03-30 | 2005-03-29 | macrocyclic compounds as viral replication inhibitors |
| NZ549697A NZ549697A (en) | 2004-03-30 | 2005-03-29 | Macrocyclic compounds as inhibitors of viral replication |
| EP05757750A EP1749007A2 (en) | 2004-03-30 | 2005-03-29 | Macrocyclic compounds as inhibitors of viral replication |
| CA2560897A CA2560897C (en) | 2004-03-30 | 2005-03-29 | Macrocyclic compounds as inhibitors of viral replication |
| AU2005228894A AU2005228894B9 (en) | 2004-03-30 | 2005-03-29 | Macrocyclic compounds as inhibitors of viral replication |
| UAA200611368A UA91677C2 (en) | 2004-03-30 | 2005-03-29 | Macrocyclic compounds as inhibitors of hcv replication |
| JP2007506466A JP4950026B2 (en) | 2004-03-30 | 2005-03-29 | Macrocyclic compounds as viral replication inhibitors |
| EA200601467A EA012389B1 (en) | 2004-03-30 | 2005-03-29 | Macrocyclic compounds as inhibitors of viral replication |
| IL177917A IL177917A0 (en) | 2004-03-30 | 2006-09-06 | Macrocyclic compounds as inhibitors of viral replication |
| TNP2006000308A TNSN06308A1 (en) | 2004-03-30 | 2006-09-27 | Macrocyclic compounds as inhibitors of viral replication |
| NO20064933A NO20064933L (en) | 2004-03-30 | 2006-10-27 | Macrocyclic compounds as inhibitors of viral replication |
| IS8563A IS8563A (en) | 2004-09-22 | 2006-10-30 | Macrocyclic compounds that inhibit viral synthesis |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55816104P | 2004-03-30 | 2004-03-30 | |
| US60/558,161 | 2004-03-30 | ||
| US56241804P | 2004-04-14 | 2004-04-14 | |
| US60/562,418 | 2004-04-14 | ||
| US61238104P | 2004-09-22 | 2004-09-22 | |
| US61246004P | 2004-09-22 | 2004-09-22 | |
| US60/612,460 | 2004-09-22 | ||
| US60/612,381 | 2004-09-22 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2005095403A2 WO2005095403A2 (en) | 2005-10-13 |
| WO2005095403A3 WO2005095403A3 (en) | 2005-12-01 |
| WO2005095403B1 true WO2005095403B1 (en) | 2006-02-02 |
Family
ID=35005653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2005/010494 WO2005095403A2 (en) | 2004-03-30 | 2005-03-29 | Macrocyclic compounds as inhibitors of viral replication |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1749007A2 (en) |
| JP (1) | JP4950026B2 (en) |
| AP (1) | AP2006003763A0 (en) |
| AR (1) | AR050321A1 (en) |
| AU (1) | AU2005228894B9 (en) |
| BR (1) | BRPI0509467A (en) |
| CA (1) | CA2560897C (en) |
| CU (1) | CU23787B7 (en) |
| EA (1) | EA012389B1 (en) |
| EC (1) | ECSP066959A (en) |
| GE (1) | GEP20104926B (en) |
| IL (1) | IL177917A0 (en) |
| MA (1) | MA28548B1 (en) |
| NO (1) | NO20064933L (en) |
| NZ (1) | NZ549697A (en) |
| WO (1) | WO2005095403A2 (en) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US7541357B2 (en) | 2004-07-15 | 2009-06-02 | Amr Technology, Inc. | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7608614B2 (en) * | 2005-03-08 | 2009-10-27 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic compounds |
| US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI387603B (en) | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Hcv ns3 protease inhibitors |
| EP2305695A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
| AU2006274861B2 (en) * | 2005-07-29 | 2012-11-08 | Medivir Ab | Macrocyclic inhibitors of hepatitis C virus |
| AR055395A1 (en) | 2005-08-26 | 2007-08-22 | Vertex Pharma | INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS |
| US7772183B2 (en) * | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2007078990A2 (en) | 2005-12-23 | 2007-07-12 | Zealand Pharma A/S | Modified lysine-mimetic compounds |
| WO2008008776A2 (en) | 2006-07-11 | 2008-01-17 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2374812B1 (en) | 2006-07-13 | 2015-04-15 | Achillion Pharmaceuticals, Inc. | 4-amino-4-oxobutanoyl Peptides as Inhibitors of Viral Replication |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN101568543B (en) * | 2006-11-16 | 2012-06-06 | 百时美施贵宝公司 | Macrocyclic peptides as hepatitis c virus inhibitors |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2074087A2 (en) | 2006-12-21 | 2009-07-01 | Wyeth | Synthesis of pyrrolidine compounds |
| CA2679563A1 (en) * | 2007-01-08 | 2008-07-17 | Phenomix Corporation | Macrocyclic hepatitis c protease inhibitors |
| WO2008096002A1 (en) * | 2007-02-08 | 2008-08-14 | Tibotec Pharmaceuticals Ltd. | Hcv inhibiting macrocyclic phosphonates and amidophosphates |
| US8435984B2 (en) | 2007-02-26 | 2013-05-07 | Achillion Pharmaceuticals, Inc. | Tertiary amine substituted peptides useful as inhibitors of HCV replication |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| US20090155209A1 (en) * | 2007-05-03 | 2009-06-18 | Blatt Lawrence M | Novel macrocyclic inhibitors of hepatitis c virus replication |
| CA2691442C (en) * | 2007-06-29 | 2014-01-21 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2009005690A2 (en) * | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Antiviral compounds |
| CN101801925A (en) | 2007-06-29 | 2010-08-11 | 吉里德科学公司 | antiviral compounds |
| SE531698C2 (en) | 2007-07-12 | 2009-07-07 | Respiratorius Ab | New bronchodilating a, b unsaturated amides |
| US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| MX2010006738A (en) | 2007-12-21 | 2010-10-15 | Avila Therapeutics Inc | Hcv protease inhibitors and uses thereof. |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| MX2010006736A (en) | 2007-12-21 | 2010-10-15 | Avila Therapeutics Inc | Hcv protease inhibitors and uses thereof. |
| US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| DK2238142T3 (en) | 2007-12-24 | 2012-10-08 | Janssen R & D Ireland | Macrocyclic indoles such as hepatitis C virus inhibitors |
| PL2276725T3 (en) * | 2008-04-11 | 2012-11-30 | Hoffmann La Roche | New ruthenium complexes as catalysts for metathesis reactions |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5529120B2 (en) | 2008-05-29 | 2014-06-25 | ブリストル−マイヤーズ スクイブ カンパニー | Hepatitis C virus inhibitor |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| ES2461841T3 (en) * | 2008-08-07 | 2014-05-21 | F. Hoffmann-La Roche Ag | Process for the preparation of a macrocycle |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (en) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS |
| BRPI0918653A2 (en) | 2008-09-17 | 2015-12-01 | Boehringer Ingelheim Int | ns3 inhibitor combination of hcv prosthesis with interferon and ribavirin. |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| DK2364309T3 (en) | 2008-12-10 | 2015-01-12 | Achillion Pharmaceuticals Inc | NEW 4-AMINO-4-OXOBUTANOYLPEPTIDER as inhibitors of viral replication |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201031675A (en) | 2008-12-23 | 2010-09-01 | Pharmasset Inc | Synthesis of purine nucleosides |
| US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
| AU2009329867B2 (en) | 2008-12-23 | 2015-01-29 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| LT2401272T (en) | 2009-02-27 | 2017-03-27 | Janssen Pharmaceuticals, Inc. | Amorphous salt of a macrocyclic inhibitor of hcv |
| WO2010118078A1 (en) | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| CN102458123A (en) | 2009-05-12 | 2012-05-16 | 阿尔巴尼分子研究公司 | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
| PE20120373A1 (en) | 2009-05-12 | 2012-05-17 | Albany Molecular Res Inc | 7 - ([1,2,4] TRIAZOLO [1,5-A] PYRIDIN-6-IL) -4- (3,4-DICHLOROPHENYL) -1,2,3,4-TETRAHYDROISOQUINOLINE |
| WO2010132487A1 (en) | 2009-05-12 | 2010-11-18 | Bristol-Myers Squibb Company | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI576352B (en) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | Nucleoside phosphoramidates |
| US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| MA33491B1 (en) | 2009-07-07 | 2012-08-01 | Boehringer Ingelheim Int | Pharmaceutical formulations of hepatitis c virus enzyme inhibitor |
| JP2013501068A (en) | 2009-08-05 | 2013-01-10 | アイディニックス ファーマシューティカルズ インコーポレイテッド | Macrocyclic serine protease inhibitor |
| CA2774387A1 (en) * | 2009-09-28 | 2011-03-31 | F. Hoffmann-La Roche Ltd | Novel macrocyclic inhibitors of hepatitis c virus replication |
| EA201200650A1 (en) | 2009-10-30 | 2012-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | COMBINED TREATMENTS OF HEPATITIS C VIRUS, INCLUDING BI201335, INTERFERON-ALPHA AND RIBAVIRIN COURSES |
| US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| EA201201031A1 (en) | 2010-01-25 | 2013-02-28 | Энанта Фармасьютиклз, Инк. | HEPATITIS C VIRUS INHIBITORS |
| TW201136945A (en) | 2010-03-31 | 2011-11-01 | Pharmasset Inc | Purine nucleoside phosphoramidate |
| HUE026235T2 (en) | 2010-03-31 | 2016-06-28 | Gilead Pharmasset Llc | Crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1-(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate |
| EP2455068A1 (en) * | 2010-11-09 | 2012-05-23 | F. Hoffmann-La Roche AG | Pharmaceutical composition for treating HCV infections |
| MX2013005454A (en) | 2010-11-15 | 2013-06-24 | Abbvie Inc | Nampt and rock inhibitors. |
| TW201242974A (en) | 2010-11-30 | 2012-11-01 | Gilead Pharmasset Llc | Compounds |
| CN103380132B (en) | 2010-12-30 | 2016-08-31 | 益安药业 | Phenanthridines macrocyclic hepatitis C serine protease inhibitors |
| JP2014502620A (en) | 2010-12-30 | 2014-02-03 | エナンタ ファーマシューティカルズ インコーポレイテッド | Macrocyclic hepatitis C serine protease inhibitor |
| AR085352A1 (en) | 2011-02-10 | 2013-09-25 | Idenix Pharmaceuticals Inc | MACROCICLIC INHIBITORS OF SERINA PROTEASA, ITS PHARMACEUTICAL COMPOSITIONS AND ITS USE TO TREAT HCV INFECTIONS |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| CN104718201A (en) | 2012-06-12 | 2015-06-17 | 艾伯维公司 | Pyridinone and pyridazinone derivatives |
| LT2909205T (en) | 2012-10-19 | 2016-12-27 | Bristol-Myers Squibb Company | 9-methyl substituted hexadecahydrocyclopropa(e)pyrrolo(1,2-a)(1,4)diazacyclopentadecinyl carbamate derivatives as non-structural 3 (ns3) protease inhibitors for the treatment of hepatitis c virus infections |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| CN105164148A (en) | 2013-03-07 | 2015-12-16 | 百时美施贵宝公司 | Hepatitis c virus inhibitors |
| KR20160005334A (en) | 2013-03-14 | 2016-01-14 | 아칠리온 파르마세우티칼스 인코포레이티드 | Novel Processes for Producing Sovaprevir |
| US9227952B2 (en) | 2013-03-15 | 2016-01-05 | Achillion Pharmaceuticals, Inc. | Sovaprevir polymorphs and methods of manufacture thereof |
| WO2014145600A1 (en) | 2013-03-15 | 2014-09-18 | Achillion Pharmaceuticals, Inc. | Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof |
| US9006423B2 (en) | 2013-03-15 | 2015-04-14 | Achillion Pharmaceuticals Inc. | Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof |
| MX2016002185A (en) | 2013-08-27 | 2016-06-06 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds. |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| CN110709096B (en) | 2017-05-05 | 2023-10-31 | 泽兰德制药公司 | Cell gap junction communication regulator and application thereof in treatment of diabetic eye disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR022061A1 (en) * | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | INHIBITING PEPTIDES OF HEPATITIS C, A PHARMACEUTICAL COMPOSITION CONTAINING THEM, THE USE OF THE SAME TO PREPARE A PHARMACEUTICAL COMPOSITION, THE USE OF AN INTERMEDIATE PRODUCT FOR THE PREPARATION OF THESE PEPTIDES AND A PROCEDURE FOR THE PREPARATION OF ANOGRAPH . |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| BR0115447A (en) * | 2000-11-20 | 2005-10-18 | Bristol Myers Squibb Co | Hepatitis C Tripeptide Inhibitors |
| US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| CA2369711A1 (en) * | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
| CA2370396A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| CA2369970A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US6869964B2 (en) * | 2002-05-20 | 2005-03-22 | Bristol-Myers Squibb Company | Heterocyclicsulfonamide hepatitis C virus inhibitors |
| AP2287A (en) * | 2003-10-14 | 2011-10-31 | Intermune Inc | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication. |
| CA2552319C (en) * | 2004-01-30 | 2012-08-21 | Medivir Ab | Hcv ns-3 serine protease inhibitors |
-
2005
- 2005-03-29 AU AU2005228894A patent/AU2005228894B9/en not_active Ceased
- 2005-03-29 BR BRPI0509467-4A patent/BRPI0509467A/en not_active IP Right Cessation
- 2005-03-29 WO PCT/US2005/010494 patent/WO2005095403A2/en active Application Filing
- 2005-03-29 NZ NZ549697A patent/NZ549697A/en not_active IP Right Cessation
- 2005-03-29 JP JP2007506466A patent/JP4950026B2/en not_active Expired - Fee Related
- 2005-03-29 EA EA200601467A patent/EA012389B1/en not_active IP Right Cessation
- 2005-03-29 EP EP05757750A patent/EP1749007A2/en not_active Withdrawn
- 2005-03-29 CA CA2560897A patent/CA2560897C/en not_active Expired - Fee Related
- 2005-03-29 GE GEAP20059674A patent/GEP20104926B/en unknown
- 2005-03-29 AP AP2006003763A patent/AP2006003763A0/en unknown
- 2005-03-30 AR ARP050101257A patent/AR050321A1/en not_active Application Discontinuation
-
2006
- 2006-09-06 IL IL177917A patent/IL177917A0/en unknown
- 2006-10-20 MA MA29407A patent/MA28548B1/en unknown
- 2006-10-27 NO NO20064933A patent/NO20064933L/en not_active Application Discontinuation
- 2006-10-27 EC EC2006006959A patent/ECSP066959A/en unknown
-
2009
- 2009-12-08 CU CU20090209A patent/CU23787B7/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005095403B1 (en) | Macrocyclic compounds as inhibitors of viral replication | |
| WO2005095403A3 (en) | Macrocyclic compounds as inhibitors of viral replication | |
| WO2007015824A3 (en) | Novel macrocyclic inhibitors of hepatitis c virus replication | |
| WO2008005511A3 (en) | Novel inhibitors of hepatitis c virus replication | |
| WO2008137779A3 (en) | Novel macrocyclic inhibitors of hepatitis c virus replication | |
| TNSN06308A1 (en) | Macrocyclic compounds as inhibitors of viral replication | |
| TN2009000481A1 (en) | Novel peptide inhibitors of hepatitis c virus replication | |
| WO2007047146A3 (en) | Inhibitors of viral replication | |
| WO2005007681A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| WO2008100867A3 (en) | Novel inhibitors hepatitis c virus replication | |
| WO2008106058A3 (en) | Inhibitors of serine proteases | |
| EA201071034A1 (en) | NEW MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATIONS | |
| WO2006039488A3 (en) | Hcv ns3-ns4a protease inhibition | |
| WO2004093798A3 (en) | Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors | |
| MY148123A (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| WO2005037214A3 (en) | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication | |
| WO2009134616A8 (en) | Novel inhibitors of hepatitis c virus replication | |
| MX2012003171A (en) | Novel macrocyclic inhibitors of hepatitis c virus replication. | |
| TNSN06103A1 (en) | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication | |
| CA2512713A1 (en) | Bicyclic carbohydrate compounds useful in the treatment of infections caused by flaviviridae sp., such as hepatitis c and bovine viral diarrhea viruses | |
| TW200611905A (en) | Macrocyclic compounds as inhibitors of viral replication | |
| UA95455C2 (en) | Macrocyclic inhibitors of hepatitis c virus replication | |
| WO2005023178A3 (en) | Acridone derivatives as anti-herpesvirus agents | |
| UA84579C2 (en) | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hepatitis c virus replication |